Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisMerrill D. Benson, Teresa Coelho, Márcia Waddington‐Cruz et al.|New England Journal of Medicine|2018Cited by 1.4k
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González‐Duarte et al.|The Lancet Neurology|2020Cited by 160
Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year updateAngela Dispenzieri, Soon-Chai Low, Teresa Coelho et al.|Orphanet Journal of Rare Diseases|2022Cited by 91
Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin AmyloidosisAngelo Giuseppe Caponetti, D. Eric Steidley, Claudio Rapezzi et al.|JACC Heart Failure|2021Cited by 80
Assessing mNIS+7<sub>Ionis</sub> and international neurologists' proficiency in a familial amyloidotic polyneuropathy trialWilliam J. Litchy, John C. Kincaid, P. James B. Dyck et al.|Muscle & Nerve|2017Cited by 56